Key result
Aliskiren maintains potassium levels without high-dose oral supplementation in Bartter syndrome.
Why the study?
Bartter syndrome features invariably elevated plasma renin activity and is traditionally treated with large doses of oral potassium, prompting investigation into whether the direct renin inhibitor aliskiren could maintain potassium levels without large oral potassium doses.
Does aliskiren maintain potassium levels without large doses of oral potassium in patients with Bartter syndrome?
Case Report (n=1)
Does aliskiren maintain potassium levels without large doses of oral potassium in patients with Bartter syndrome?
This case report provides the first documented evidence of the efficacy of the direct renin inhibitor aliskiren in maintaining potassium levels in Bartter syndrome.
Answers are grounded in this paper and cite their sources.
May support aliskiren for potassium control in Bartter syndrome; hypothesis-generating and leaves open need for trials.
Bartter syndrome is traditionally treated with large doses of oral potassium with or without suppression of the renin-angiotensin system. Since plasma renin activity is invariably elevated in Bartter syndrome, the availability of the direct renin inhibitor aliskiren should lead to the ability to maintain potassium levels without utilizing large doses of oral potassium. This case report is, to my knowledge, the first to show the efficacy of a renin receptor blocker in Bartter syndrome.
No takes yet. Share an insight, caveat, or question.
David S.H. Bell (2009) conducted a case report in Bartter syndrome (n=1). Aliskiren was evaluated on Maintenance of potassium levels without utilizing large doses of oral potassium. Aliskiren demonstrated efficacy in maintaining potassium levels without large doses of oral potassium in a case report of Bartter syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: